Moderna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults

Reuters04-07

<a href="https://laohu8.com/S/MRNA">Moderna</a> says mRNA-1010 flu shot shows similar immune response on revaccination in older adults

Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.
Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.
Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.
Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625602719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625602719","market":"nz","top_or_hot":-1,"title":"Moderna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> says mRNA-1010 flu shot shows similar immune response on revaccination in older adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.\n        </li>\n<li>\n          Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.\n        </li>\n<li>\n          Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.\n        </li>\n<li>\n          Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-07 06:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> says mRNA-1010 flu shot shows similar immune response on revaccination in older adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.\n        </li>\n<li>\n          Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.\n        </li>\n<li>\n          Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.\n        </li>\n<li>\n          Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL50ZPzx:1","article_id":"2625602719","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625602719","pubTimestamp":1775513243,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","MRNY":"MRNA期权收益策略ETF-YieldMax","MRNA":"Moderna, Inc."},"translate_title":"Moderna表示，mRNA-1010流感疫苗在老年人中重新接种疫苗时显示出类似的免疫反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNY":0.6,"MRNA":0.9,"MRNX":0.6},"content_text":"Moderna says mRNA-1010 flu shot shows similar immune response on revaccination in older adults\n    \n\n\n          Moderna scheduled late-breaking presentations at ESCMID Global Congress in Munich on April 18 covering revaccination data for investigational seasonal flu shot mRNA-1010 and RSV vaccine mRESVIA.\n        \n\n          Flu revaccination analysis in adults 50 and older showed immune responses held up across prior vaccine histories, with no new safety issues reported.\n        \n\n          Interim Phase 3 data for mRESVIA as a booster in adults 60 and older previously given a protein-based RSV vaccine indicated it was well tolerated, with responses consistent with restoring protection.\n        \n\n          Regulatory reviews for mRNA-1010 are underway in US, Europe, Canada, Australia, with first potential approvals expected in 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625602719","isCrawlerRequest":true}